Industry Satellite symposia

Listed by symposium “slot” order

ESMO bears no responsibility for the Industry Satellite symposia. Product promotion at the ESMO Congress: Advertising of a specific product does not mean acceptance by ESMO and it is the full responsibility of the corporation that it is in accordance with the Swiss and European law, where applicable. Without responsibility for any misprints.
Friday, 8 October 2010

09.00–11.00  Pink Hall
Industry Satellite symposium
Eisai
Beyond taxanes: Rediscovering tubulin
in MBC with a targeted chemotherapy
Chair: Luca Gianni, Milan, Italy

09.00  Being There: Goals and Evidence in Current MBC Treatment
Luca Gianni, Milan, Italy

09.10  Microtubules in Anticancer Therapies: Mechanisms, Dynamics and Effects
Leslie Wilson, Santa Barbara, USA

09.30  Results and Tolerability With a Novel Non-taxane Microtubule Dynamics Inhibitor
Linda Vahdat, New York, USA

09.50  EMBRACE: Option for Improved Survival with Monotherapy in Late-stage MBC
Christopher Twelves, Leeds, UK

10.10  Real World Experience with Monotherapy for MBC
Véronique Diéras, Paris, France

10.25  Looking to the Future of Late-stage Therapy of MBC: Innovation and Hope
Luca Gianni, Milan, Italy

10.45  Faculty Discussion
Friday

09.00–09.55 Red Hall

Industry Satellite symposium
AstraZeneca
Part 1. Identifying and targeting EGFR mutations in NSCLC: personalised treatment and gefitinib
Chair: Lucio Crinò, Perugia, Italy

09.00 Chairman’s welcome and introduction
Lucio Crinò, Perugia, Italy
09.05 Everyday challenges in treating patients with EGFR mutation-positive tumours
Michael Cullen, Birmingham, UK
09.20 How did EGFR mutation testing become routine in Japan?
Tetsuya Mitsudomi, Nagoya, Japan
09.40 Panel discussion
Lucio Crinò, Michael Cullen and Tetsuya Mitsudomi
09.50 Closing remarks
Lucio Crinò, Perugia, Italy
09.55 Close of Part 1 and audience exchange
10.05–11.00 Red Hall
Industry Satellite symposium
AstraZeneca
Chair: John Forbes, Newcastle, New South Wales, Australia

10.05 Chairman’s welcome and introduction
John Forbes, Newcastle, New South Wales, Australia

10.08 ATAC – 10 years on…
John Forbes, Newcastle, New South Wales, Australia

10.23 Treatment options in advanced breast cancer – optimising efficacy with fulvestrant 500mg
Guy Jerusalem, Liege, Belgium

10.38 CONFIRM: Translating the data into clinical practice
Christian Jackisch, Offenbach, Germany

10.53 Audience questions
All faculty

10.59 Closing remarks
John Forbes, Newcastle, New South Wales, Australia
Industry Satellite symposium
Novartis
Patient management throughout the disease continuum in genitourinary malignancies
Chair: Peter Mulders, Nijmegen, The Netherlands

09.00 Welcome and Opening Remarks
Peter Mulders, Nijmegen, The Netherlands

09.05 Case Study 1: Renal Cell Carcinoma – Strategies for Patient Management Across the Disease Continuum: TKIs and Beyond
Giampaolo Tortora, Naples, Italy and Kurt Miller, Berlin, Germany

09.50 Q&A
Peter Mulders, Giampaolo Tortora, Andrea Tubaro and Bertrand Tombal

10.00 Case Study 2: Prostate Cancer – Caring for the Patient From Initial Diagnosis Through End-stage Disease
Andrea Tubaro, Rome, Italy and Bertrand Tombal, Brussels, Belgium

10.30 Future Directions With Bone-Targeted Therapies in GU Malignancies
Peter Mulders, Nijmegen, The Netherlands

10.45 Q&A
Peter Mulders, Giampaolo Tortora, Andrea Tubaro and Bertrand Tombal

10.55 Concluding Remarks
Peter Mulders, Nijmegen, The Netherlands
09.00–10.30 Orange Halls 1+2+3
Industry Satellite symposium
Boehringer Ingelheim
Spotlight on novel targets and rational combinations
Chair: Giorgio Scagliotti, Orbassano, Italy

09.00 Chair’s introduction and welcome
Giorgio Scagliotti, Orbassano, Italy
09.10 Plk1 inhibition: pioneering novel targets
Patrick Schöffski, Leuven, Belgium
09.30 Novel anti-angiogenic agents in NSCLC:
a multi-target approach
Giorgio Scagliotti, Orbassano, Italy
09.50 Exploring the role of anti-angiogenic agents
in ovarian cancer
Robert Coleman, Houston, USA
10.10 Q&A
11.00–13.00 Orange Halls 1+2+3
Industry Satellite symposium
Boehringer Ingelheim
New light, new hope in targeted therapy
Chair: Frederico Cappuzzo, Livorno, Italy

11.00 Chair’s introduction and welcome
Frederico Cappuzzo, Livorno, Italy
11.10 Are EGFR inhibitors living up to their promise in NSCLC?
Eckart Laack, Hamburg, Germany
11.30 Biomarkers in NSCLC: Are we there yet?
Ken O’Byrne, Dublin, Ireland
11.50 Refreshing our perspective: inhibiting HER signalling in breast cancer
Charles Swanton, London, UK
12.10 Renewed hope in head and neck cancer: targeting EGFR
Ezra Cohen, Chicago, USA
12.30 Q&A
11.00–13.00 Silver Hall

Industry Satellite symposium

Pfizer Oncology

Endocrine treatment in breast cancer – going beyond the obvious

Chair: Robert Coleman, Sheffield, UK

11.00 Introduction
Robert Coleman, Sheffield, UK

11.05 Metastatic breast cancer: Balancing quality of life and prolongation of survival
Nadia Harbeck, Cologne, Germany

11.20 Panel discussion/Questions & Answers
All faculty

11.40 How to assess post-menopausal status in breast cancer patients to optimize treatment?
Alison Jones, London, UK

11.55 Panel discussion/Questions & Answers
All faculty

12.15 Elderly women with breast cancer: Can they handle more than they get?
Matti S. Aapro, Genolier, Switzerland

12.30 Panel discussion/Questions & Answers
All faculty

12.50 Summary and conclusions
Robert Coleman, Sheffield, UK
11.00–13.00  Green Halls 1+2  
**Industry Satellite symposium**  
MSD Oncology  
Targeted therapeutics & patient selectivity:  
Improving outcomes in oncology clinical research  
Chair: Paul Baas, Amsterdam, The Netherlands

11.00  Welcome and introduction  
Paul Baas, Amsterdam, The Netherlands  

11.05  The Rationale for Histone Deacetylase Inhibitors in Solid Tumors  
Paul Baas, Amsterdam, The Netherlands  

11.30  Patient Selection for Adjuvant Therapy in High-Risk Malignant Melanoma  
Axel Hauschild, Kiel, Germany  

12.00  mTOR Inhibitors Single Agent & Unique Combinations  
Jean-Yves Blay, Lyon, France  

12.25  Evidence-Based Management of CINV: Where are we today?  
Richard Gralla, New York, USA  

12.50  Panel Discussion  
Paul Baas, Amsterdam, The Netherlands
11.00–13.00 Yellow Hall 3
Industry Satellite symposium
Sigma-Tau
Cancer: the bioenergetic challenge
Chair: Gianfranco Peluso, Naples, Italy

11.00 Welcome and introduction
Gianfranco Peluso, Naples, Italy

11.15 Bioenergetics of metabolism in cancer
Vittorio Calabrese, Catania, Italy

11.40 Targeting metabolic transformation for cancer therapy
Eyal Gottlieb, Glasgov, UK

12.05 Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role for carnitine system
Maurizio D’Incalci, Milan, Italy

12.30 Discussion and Q&A
13.00–15.00  Pink Hall
Industry Satellite symposium
Eli Lilly
Debating the full monty in advanced non-small cell lung cancer
Chair: Andrea Ardizzoni, Parma, Italy

13.00 Welcome and introduction
Andrea Ardizzoni, Parma, Italy

13.05 Selecting patients for treatment in advanced NSCLC:
  Microscopic vs Molecular
  Moderator: Peter Harper, London, UK
  Microscopic
  Giorgio Scagliotti, Orbassano, Italy
  Molecular
  Thierry Le Chevalier, Villejuif, France

14.00 Prioritising treatment strategies in advanced NSCLC:
  First-line vs Maintenance
  Moderator: Peter Harper, London, UK
  First-line
  Nick Thatcher, Manchester, UK
  Maintenance therapy
  Frances A Shepherd, Toronto, Canada

14.55 Closing remarks
Andrea Ardizzoni, Parma, Italy
13.00–14.30  Red Hall
Industry Satellite symposium
Novartis Oncology
Navigating Advanced Net: A Journey Through Clinical Management
Symposium Faculty: Guido Rindi, Rome Italy; Kjell Öberg, Uppsala, Sweden; Marianne Pavel, Berlin, Germany and James Yao, Houston, USA

13.00  Welcome and introduction
   Guido Rindi, Rome Italy
13.05  State-of-the-Art Review of NET in 2010
   Kjell Öberg, Uppsala, Sweden
13.25  State-of-the-Art Review of NET in 2010 Q/A Session
   Panel discussion
13.35  Current Challenges in the Management of Advanced NET: The Experts’ Opinion
   Marianne Pavel, Berlin, Germany
13.50  Current Challenges in the Management of Advanced NET: The Experts’ Opinion Q/A Session
   Panel discussion
14.00  Practice Changing Clinical Trials in NET
   James Yao, Houston, USA
14.15  Practice Changing Clinical Trials in NET Q/A Session
   Panel Discussion
14.25  Closing Remarks
   Guido Rindi, Rome Italy
13.00–15.00 Blue Hall

**Industry Satellite symposium**

**Pfizer Oncology**

**Achieving optimal outcomes with targeted agents for RCC: Now and in the future**

**Chair:** Martin Gore, London, UK

---

13.00 Welcome and introduction
   Martin Gore, London, UK

13.10 How guidelines influence the approach in Europe to the treatment of advanced RCC
   Joaquim Bellmunt, Barcelona, Spain

13.30 Making treatment decisions in clinical practice
   Manuela Schmidinger, Vienna, Austria

13.50 Q&A
   Martin Gore, Joaquim Bellmunt, Manuela Schmidinger, Alain Ravaud and Nicholas Vogelzang

14.00 Achieving a continuum of care: Overcoming resistance through sequential treatment
   Alain Ravaud, Bordeaux, France

14.20 An evolving landscape: Current worldwide trials
   Nicholas Vogelzang, Las Vegas, USA

14.40 Q&A
   Martin Gore, Joaquim Bellmunt, Manuela Schmidinger, Alain Ravaud and Nicholas Vogelzang

14.50 Summary and close
   Martin Gore, London, UK
15.00–17.00  **Violet Hall**  
**Industry Satellite symposium**  
Roche  
Part 1. Transforming the treatment landscape: angiogenesis inhibition in cancer  
Chair: Martin Gore, London, UK

15.00 Controlling tumour growth through angiogenesis inhibition  
Martin Gore, London, UK

15.10 Patient-driven treatment strategies in CRC  
Cornelis Punt, Nijmegen, Netherlands

15.30 Optimising patient outcomes in mBC with anti-angiogenic therapy  
Rebecca Dent, Toronto, Canada

15.50 Anti-VEGF therapy: innovating NSCLC treatment  
Roman Perez-Soler, New York, USA

16.10 Role of angiogenesis in GBM  
Jeffrey Raizer, Chicago, USA

16.30 Clinical data update: anti-angiogenesis in front-line ovarian cancer  
Robert Burger, Philadelphia, USA

16.50 Meeting close  
Martin Gore, London, UK
15.00–16.30 Silver Hall
Industry Satellite symposium
Merck Serono
Personalized treatment – A new standard for prolonging overall survival in mCRC
Chairs: Alberto Sobrero, Genoa, Italy and Eric Van Cutsem, Leuven, Belgium

15.00 Welcome and introduction
   Alberto Sobrero, Genoa, Italy
15.10 Prolonging survival through a personalized approach in mCRC
   Carsten Bokemeyer, Hamburg, Germany
15.35 Tumor shrinkage impacts long-term outcomes in mCRC
   Sabine Tejpar, Leuven, Belgium
15.55 Perspectives on resection in mCRC
   Wolf Bechstein, Frankfurt/ Main, Germany
16.15 Summary and close
   Eric Van Cutsem, Leuven, Belgium
15.00–16.30 Red Hall
**Industry Satellite symposium**
Novartis
Emerging Treatment Options Across the Breast Cancer Continuum
Chair: Peter Dubsky, Vienna, Austria

15.00 Welcome and Opening Remarks
Peter Dubsky, Vienna, Austria

15.05 Endocrine therapy approaches for postmenopausal hormone-responsive breast cancer: Maximizing the benefit
Joseph Gligorov, Paris, France

15.25 Potential anticancer properties of bisphosphonates: Rationale
Francesco Bertoldo, Verona, Italy

15.45 Treatment considerations in breast cancer: Beyond endocrine therapy
Peter Dubsky, Vienna, Austria

16.00 Promising agents in ER+ and HER2+ breast cancer: mTOR and beyond
Fabrice André, Villejuif, France

16.20 Panel discussion: Managing breast cancer – treating the patient, not the disease
Peter Dubsky, Joseph Gligorov, Francesco Bertoldo and Fabrice André
15.00–16.30 Green Halls 1+2
Industry Satellite symposium
prIME Oncology, Part I
Triple-Negative Breast Cancer:
On the Pathway to Better Outcomes
Chair: Ian Smith, London, United Kingdom

15.00 Welcome, introduction, and demographics
   Ian Smith, London, UK
15.05 Clinical opinion poll question
15.10 Understanding the biology of triple-negative breast cancer (TNBC)
   Giuseppe Viale, Milan, Italy
15.25 Panel commentary
15.30 Clinical opinion poll question
15.35 Triple-negative breast cancer:
   What we know and what we don’t know
   Nadia Harbeck, Cologne, Germany
15.50 Panel commentary
15.55 Clinical opinion poll question
16.00 PARP inhibition: Why it works in TNBC
   John Pippen, Dallas, USA
16.20 Panel commentary
16.25 Take home messages and future directions
   Ian Smith, London, UK
16.30–18.30  Pink Hall

Industry Satellite symposium
Janssen Pharmaceutical Companies of Johnson & Johnson
New treatment options for patients with relapse ovarian cancer or advanced prostate cancer
Chair: Mario Dicato, Luxembourg

16.30  Welcome and Introduction — Unmet medical needs and requirement for new treatment options for patients with relapsed ovarian and advanced prostate cancer
Mario Dicato, Luxembourg

16.40  Are new treatment possibilities changing the standard of care in relapsed ovarian cancer?
Eric Pujade-Lauraine, Paris, France

17.00  Panel discussion — State of the art in relapsed ovarian cancer
Mario Dicato, Eric Pujade-Lauraine and Andres du Bois

17.15  A new paradigm in advanced prostate cancer: from hormone-refractory to castrate-resistant prostate cancer
Bertrand Tombal, Brussels, Belgium

17.35  Non-endocrine targets and new drugs for castrate-resistant prostate cancer
Karim Fizazi, Villejuif, France

17.55  Overcoming resistance to hormonal treatment with novel androgen biosynthesis inhibitors
Johann de Bono, Sutton, UK

18.15  Panel discussion — Current status and future possibilities for patients with advanced prostate cancer
Mario Dicato, Johann de Bono, Karim Fizazi and Bertrand Tombal, Brussels, Belgium

18.30  Concluding remarks
Mario Dicato, Luxembourg
Industry Satellite symposium
sanofi aventis
Beyond docetaxel – New treatment options in mHRPC
Chair: Luigi Dogliotti, Orbassano, Italy

16.30 Meeting opening – Welcome and introduction
   Luigi Dogliotti, Orbassano, Italy
16.40 Overcoming taxane resistance – New solution for an old problem
   Stéphane Oudard, Paris, France
17.00 Management of mHRPC patients previously treated with docetaxel – Evidence of survival benefits
   Oliver Sartor, New Orleans, USA
17.40 New treatment options for mHRPC patients: When and whom to consider – A case study
   Jean-Pascal Machiels, Brussels, Belgium
18.20 Summary of key findings
   Luigi Dogliotti, Orbassano, Italy
16.30–18.30 Orange Halls 2+3
Industry Satellite Symposium
Cephalon
Maximizing the cornerstone of cancer therapy in the era of targeted therapies
Chairs: Frans Erdkamp, Sittard-Geleen, The Netherlands and Luca Gianni, Milan, Italy

16.30 Introduction
Luca Gianni, Milan, Italy
16.45 Anthracyclines: an open field for research in 2010
Christopher Twelves, Leeds, UK
17.05 Novel approach in the treatment of HER2-positive breast cancer patients
Antonio Llombart-Cussac, Lleida, Spain
17.25 “Mysight”: breast cancer treatment in clinical practice
Frans Erdkamp, Sittard-Geleen, The Netherlands
17.45 Optimizing anthracycline use in oncology
Massimo Federico, Modena, Italy
18.05 Interactive session and discussion
Luca Gianni, Milan, Italy
16.30–18.30 Yellow Hall 1
Industry Satellite symposium
Pfizer Oncology
Opioid Use in Cancer Patients: Focus on Side Effect Management

16.30 Opioid Availability and Use in Cancer Patients within Europe
Augusto Caraceni, Milan, Italy

17.00 Managing the Side Effects of Opioids
Stein Kaasa, Trondheim, Norway

17.30 Methylnaltrexone: A Targeted Treatment for Opioid-Induced Constipation in the Palliative Care Setting
Gail Austin Cooney, West Palm Beach, USA

18.00 Questions and Answers
16.45–18.30 Green Halls 1+2

Industry Satellite symposium
prIME Oncology, Part II
Challenging Cases in Contemporary Breast Oncology
Chair: Ian Smith, London, UK

16.45 Welcome and Introduction
Ian Smith, London, UK

16.50 Case #1 – Targeted therapy for HER2-overexpressing metastatic breast cancer
Sunil Verma, Toronto, Canada

17.15 Faculty panel discussion

17.20 Case #2 – Strategies for improving outcomes in HER2-negative breast cancer
José Baselga, Boston, USA

17.45 Faculty panel discussion

17.50 Case #3 – Risk assessment and treatment planning in early breast cancer: How can we determine optimal therapeutic strategies?
Fabrice André, Villejuif, France

18.15 Faculty panel discussion

18.20 Concluding remarks and summary of key take-home messages
Ian Smith, London, UK
17.00–18.30 Silver Hall
Industry Satellite symposium
Merck Serono
New standards in the treatment of SCCHN
Chairs: Lisa Licitra, Milan, Italy and Marco C. Merlano, Cuneo, Italy

17.00 Welcome and introduction
Lisa Licitra, Milan, Italy

17.10 Optimizing the treatment in locally advanced SCCHN
Jacques Bernier, Genolier, Switzerland

17.30 Integrating ERBITUX into routine clinical practice in LA SCCHN – a real world case study
Jean Bourhis, Villejuif, France

17.45 EXTREME – a new treatment standard for 1st-line recurrent and/or metastatic SCCHN
Ulrich Keilholz, Berlin, Germany

18.05 Integrating ERBITUX into routine clinical practice in 1st-line recurrent and/or metastatic SCCHN – a real world case study
Sandrine Faivre, Paris, France

18.20 Closing remarks
Marco Merlano, Cuneo, Italy
17.20–18.30 Violet Hall
Industry Satellite symposium
Roche
Chair: Lucio Crinò, Perugia, Italy

17.20 Welcome and introduction:
   Lucio Crinò, Perugia, Italy
17.25 Current and future biomarkers in NSCLC: making innovation a reality
   Kenneth O’Byrne, Dublin, Ireland
17.45 Understanding the benefits of anti-VEGF therapy: why, when and who?
   Lucio Crinò, Perugia, Italy
18.05 Optimising treatment success with maintenance therapy in NSCLC
   Federico Cappuzzo, Livorno, Italy
18.25 Summary and close
   Lucio Crinò, Perugia, Italy
Sunday, 10 October 2010

17.30–19.30 Silver Hall
Industry Satellite symposium
Amgen
RANK Ligand inhibition for bone health in cancer patients – Targeted toward a new standard of care
Chair: Robert Coleman, Sheffield, UK

17.30 The central role of the RANK Ligand pathway in cancer treatment induced bone loss
Bertrand Tombal, Brussels, Belgium
RANK Ligand inhibition – improving care in men with advanced prostate cancer
Karim Fizazi, Villejuif, France
Challenging the current standard for prevention of bone complications in the advanced cancer setting
Allan Lipton, Hershey, USA
Working towards prevention of bone metastases with innovative adjuvant therapies
Robert Coleman, Sheffield, UK
Industry Satellite symposium
Bayer
From discovery to personalized medicine: evolving paradigms in cancer treatment
Co-chairmen: Bernard Escudier, Villejuif, France; Josep M. Llovet, Barcelona, Spain and New York, USA

17.30 Welcome
Bernard Escudier, Villejuif, France

17.35 Evolution of a targeted therapy in cancer: the past, present, and future
Bernard Escudier, Villejuif, France

17.45 Current and future treatment options in renal cell carcinoma
Timothy Eisen, Cambridge, UK

18.05 Broadening horizons in the treatment of hepatocellular carcinoma
Josep M. Llovet, Barcelona, Spain and New York, USA

18.20 Integrating the standard of care in HCC in the clinical practice
Jean-Luc Raoul, Rennes, France

18.35 Emerging treatment options in differentiated thyroid cancer
Marcia S. Brose, Philadelphia, USA

18.50 The role of targeted therapies in HER2 negative metastatic breast cancer
Angelo Di Leo, Prato, Italy

19.05 The shifting paradigm in the treatment of NSCLC: from combination therapy to personalized medicine
George R. Blumenschein, Houston, USA

19.20 Panel discussion

19.25 Concluding remarks
Josep M. Llovet, Barcelona, Spain and New York, USA
Industry Satellite symposium
Vifor Pharma
The evolving role of I.V. iron in cancer patients – expert recommendations and discussion
Chair: Matti S. Aapro, Genolier, Switzerland

17.30 Welcome and introduction
Matti S. Aapro, Genolier, Switzerland
17.35 Iron deficiency and anaemia – frequent comorbidities in cancer patients
18.00 Iron – availability counts, not just storage
18.25 I.V. iron – from supplementary treatment to monotherapy
18.50 Any limits to the use of I.V. iron in clinical routine?
19.15 Expanding the role of iron in oncology
19.25 Outcomes and conclusions
Matti S. Aapro, Genolier, Switzerland

Experts in the fields of anaemia management and iron deficiency give key evidence-based presentations, followed by focused panel debate and interactive discussions.

The faculty: Matti S. Aapro (Moderator); Heinz Ludwig, Vienna, Austria; Yves Beguin, Liège, Belgium and Pere Gascón, Barcelona, Spain
Industry Satellite symposium
GlaxoSmithKline
The new TKI: How do you integrate pazopanib into the treatment paradigm of mRCC?
Chair: Cora N. Sternberg, Rome, Italy

17.45 Welcome and introduction
Cora N. Sternberg, Rome, Italy

17.50 Development of pazopanib for mRCC
Cora N. Sternberg, Rome, Italy

18.05 Clinical evidence for pazopanib in mRCC
Cora N. Sternberg, Rome, Italy
  Data in the spotlight: Interactive debate
  Challenges: Stéphane Oudard
  Defence: Cora N. Sternberg, Rome, Italy

18.35 Selectivity of TKIs—does it matter?
  Challenges and debates on the issues around selecting the appropriate TKI for patients
  John Wagstaff, Swansea, UK
  Which TKI? Interactive debate
  Challenges: Joaquim Bellmunt
  Defence: John Wagstaff, Swansea, UK

18.55 Progress in overcoming drug resistance in treatment of mRCC
Joaquim Bellmunt, Barcelona, Spain

19.10 Integrating pazopanib into the treatment paradigm of mRCC
Discussion moderated by Cora N. Sternberg, Rome, Italy
  Case 1: Managing a patient with mRCC – new treatment options?
  Stéphane Oudard, Paris, France
  Case 2: Pazopanib in real-life clinical practice
  John Wagstaff, Swansea, UK

19.35 Closing remarks and questions
Cora N. Sternberg, Rome, Italy
Monday, 12 October 2010

17.45–19.45  **Violet Hall**
**Industry Satellite symposium**
Amgen (EUROPE) GmbH
Novel biologics for key pathways
Chairs: David Cunningham, Sutton, UK and
Jan Vermorken, Edegem, Belgium

17.45  Opening remarks
David Cunningham, Sutton, UK

17.50  Changing paradigms in SCCHN* treatment demand effective management of toxicities (*SCCHN, squamous cell carcinoma of the head and neck)
Jean Bourhis, Villejuif, France

18.15  Panitumumab with cisplatin and 5-FU as 1st-line treatment of recurrent or metastatic SCCHN*: the phase III SPECTRUM study (*SCCHN, squamous cell carcinoma of the head and neck)
Jan Vermorken, Edegem, Belgium

18.40  Panitumumab in the management of colorectal cancer
Gunnar Folprecht, Dresden, Germany

19.05  Future perspectives: Amgen’s investigational compounds in gastrointestinal cancer
Ramon Salazar, Barcelona, Spain

19.30  Panel discussion

19.40  Closing remarks
David Cunningham, Sutton, UK
17.45–19.45  Green Halls 1+2

Industry Satellite symposium
Bristol-Myers Squibb
Recent advances in immunotherapy for advanced melanoma
Chairs: Alexander M. M. Eggermont, Rotterdam, The Netherlands
and Giorgio Parmiani, Milan, Italy

17.45 Welcome and Introduction
Giorgio Parmiani, Milan, Italy

18.00 Cancer and the immune system
Ignacio Melero, Pamplona, Spain

18.30 Challenges of immunotherapy in advanced melanoma
Reinhard Dummer, Zurich, Switzerland

19.00 Is immunotherapy going to change the treatment paradigm in advanced melanoma?
Alexander M. M. Eggermont, Rotterdam, The Netherlands

19.30 Panel Discussion
Alexander M. M. Eggermont, Rotterdam, The Netherlands
and Giorgio Parmiani, Milan, Italy
Industry Satellite symposium
Hospira
New options for the treatment and support of patients with mesothelioma: emerging data on thymidylate synthase inhibitors
Chair: Kosta Syrigos, Athens, Greece

17.45–19.45 Orange Halls 2+3

17.45 Pre-symposium refreshments

18.15 Welcome and introduction
Kosta Syrigos, Athens, Greece

18.20 Rare, difficult and controversial: epidemiology and clinical practice in mesothelioma
Mary O’Brien, Sutton, UK

18.45 Mesothelioma and new research on thymidylate synthase inhibitors and platinum compounds
Jan van Meerbeeck, Ghent, Belgium

19.10 Sticking to the blueprint: growth factor support in chemotherapy
Cornelius Waller, Freiburg, Germany

19.35 Conclusions and discussion
Kosta Syrigos, Athens, Greece
17.45–19.15 Yellow Halls 2+3  
Industry Satellite symposium  
Novartis  
Adjuvant therapy duration and evolving data in GIST management  
Chair: George D. Demetri, Boston, USA

17.45 Welcome & Introduction  
George D. Demetri, Boston, USA
17.50 Case 1: A patient with an intermediate risk GIST  
George D. Demetri, Boston, USA
18.05 Point – counter point discussion: Should all intermediate risk patients be treated with adjuvant therapy?  
Yoon-Koo Kang, Seoul, Republic of Korea and Peter Reichardt, Bad Saarow, Germany
18.15 Case 2: A patient with a primary GIST with an exon 9 mutation  
Peter Reichardt, Bad Saarow, Germany
18.30 Point – counter point discussion: What is the relevance of imatinib dose in the adjuvant setting?  
George D. Demetri, Boston, USA and Yoon-Koo Kang, Seoul, Republic of Korea
18.40 Case 3: A patient with a high risk GIST on adjuvant therapy  
Yoon-Koo Kang, Seoul, Republic of Korea
18.55 Point – counter point discussion: What duration of adjuvant therapy?  
George D. Demetri, Boston, USA and Peter Reichardt, Bad Saarow, Germany
19.05 Closing remarks  
George D. Demetri, Boston, USA